CliffBio
biologic

N/A

penpulimab-kcqx

Loss of exclusivityApril 2037projected — 12-year biologic exclusivity estimate
CompanyAkeso Biopharma →View the full company profile on CliffBio

Drug detail

Brand nameN/A
Active ingredientpenpulimab-kcqx
Strength100MG/10ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

N/A patent cliff — loss of exclusivity April 2037 | CliffBio